Toripalimab and chemo for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of the immunotherapy drug toripalimab with standard chemotherapy for people with advanced small cell lung cancer that has gotten worse after previous treatments. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (extensive stage) small cell lung cancer.
- You have either never had immunotherapy, or you have had it before and it worked for at least 3 months but has since stopped working (and you've had at least 2 prior treatments).
- You have never used the drug anlotinib.
- You are in fairly good general health (able to care for yourself, up and about more than half of waking hours).
- Your major organs (like heart, liver, kidneys, bone marrow) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a real-world experience (not a strict experiment) for people with extensive-stage small cell lung cancer who are about to start treatment with the immunotherapy drug toripalimab. It simply tracks how you do during your regular care.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This trial tests a combination of two drugs, toripalimab and anlotinib, as maintenance therapy after initial treatment for extensive stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from growing for as long as possible.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.